D
Daniel Pink
Researcher at University of Greifswald
Publications - 121
Citations - 5797
Daniel Pink is an academic researcher from University of Greifswald. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 27, co-authored 93 publications receiving 4556 citations. Previous affiliations of Daniel Pink include Imperial College London & Humboldt State University.
Papers
More filters
Journal ArticleDOI
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Salah-Eddin Al-Batran,Nils Homann,Claudia Pauligk,Thorsten Oliver Goetze,Johannes Meiler,Stefan Kasper,Hans-Georg Kopp,Frank Mayer,Georg Martin Haag,Kim Barbara Luley,U. Lindig,Wolff Schmiegel,Michael Pohl,Jan Stoehlmacher,Gunnar Folprecht,Stephan Probst,Nicole Prasnikar,Wolfgang Fischbach,Rolf Mahlberg,Jörg Trojan,Michael Koenigsmann,Uwe M. Martens,Peter C. Thuss-Patience,Matthias Egger,Andreas Block,Volker Heinemann,Gerald Illerhaus,Markus Moehler,Michael Schenk,Frank Kullmann,Dirk M Behringer,Michael Heike,Daniel Pink,Christian Teschendorf,Carmen Löhr,Helga Bernhard,G. Schuch,Volker Rethwisch,Ludwig Fischer von Weikersthal,Jörg T. Hartmann,Michael Kneba,Severin Daum,Karsten Schulmann,Jörg Weniger,Sebastian Belle,Timo Gaiser,Fuat Oduncu,Martina Güntner,Wael Hozaeel,Alexander Reichart,Elke Jäger,Thomas Kraus,Stefan Mönig,Wolf O. Bechstein,Martin Schuler,Harald Schmalenberg,Ralf Hofheinz,Flot Aio Investigators +57 more
TL;DR: In this article, the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin, and doceteaxel) as a perioperative therapy for patients with locally advanced, resectable tumours was reported.
Journal ArticleDOI
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Heikki Joensuu,Mikael Eriksson,Kirsten Sundby Hall,Jörg T. Hartmann,Daniel Pink,Jochen Schütte,Giuliano Ramadori,Peter Hohenberger,Justus Duyster,Salah-Eddin Al-Batran,Marcus Schlemmer,Sebastian Bauer,Eva Wardelmann,Maarit Sarlomo-Rikala,Bengt Nilsson,Harri Sihto,Odd R. Monge,Petri Bono,Raija Kallio,Aki Vehtari,M. Leinonen,Thor Alvegård,Peter Reichardt +22 more
TL;DR: Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo and overall survival of GIST patients with a high risk of Gist recurrence.
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor
Journal ArticleDOI
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Eva Wardelmann,Sabine Merkelbach-Bruse,Katharina Pauls,Nadja Thomas,Hans-Ulrich Schildhaus,Thomas Heinicke,Nicola Speidel,Torsten Pietsch,Reinhard Buettner,Daniel Pink,Peter Reichardt,Peter Hohenberger +11 more
TL;DR: The identification of newly acquired KIT mutations in addition to the primary mutation is dependent on the number of tissue samples analyzed and has high implications for further therapeutic strategies.
Journal ArticleDOI
Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour
Peter Hohenberger,U Ronellenfitsch,O. Oladeji,Daniel Pink,Philipp Ströbel,Eva Wardelmann,Peter Reichardt +6 more
TL;DR: This study assessed the outcomes of patients with a gastrointestinal stromal tumour (GIST) that ruptured before or during resection.